Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab After Chemoradiotherapy (DART) for NSCLC
2019-002537-11Phase 2Active
- Sponsor
- Oslo University Hospital
- Start
- Nov 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Oslo University Hospital. Primary endpoint: Primary: Hazard ratio for high TMB vs low TMB. Started Nov 2019; status: active.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-002537-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002537-11.